US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

48.98

+0.54001.11%

Volume:42.58K

Turnover:2.08M

Market Cap:14.98B

PE:21.97

High:49.03

Open:48.70

Low:48.65

Close:48.44

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.21

T/O Rate:0.01%

Dividend:2.10

Dividend Rate:4.28%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.61

PE(LYR):19.87

Loading ...

Overview Company News Filings

Analysts Are Bullish on These Utilities Stocks: Emera (EMA), Edenor SA (EDN)

Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Emera price target lowered to C$76 from C$77 at CIBC

Barclays Keeps Their Hold Rating on Emera (EMA)

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Stock Track | Emera Inc. Plunges 6.78% in Pre-market Trading After Q2 Earnings Miss Analyst Estimates

Emera Q2 Adjusted Earnings Fall, Revenue Rises

MT Newswires Live

Emera Q2 Adj. EPS $0.50 Misses $0.56 Estimate

Benzinga Earnings

Press Release: Emera Reports 2026 Second Quarter Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Press Release: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Emera Inc Expected to Post Earnings of 49 Cents a Share - Earnings Preview

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval

Simply Wall St.

Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/EMA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":48.98,"timestamp":1789578820529,"preClose":48.44,"halted":0,"volume":42580,"delay":0,"changeRate":0.01114781172584639,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Trading","change":0.54,"latestTime":"09-16 13:13:41 EDT","open":48.7,"high":49.03,"low":48.65,"amount":2081743.14054,"amplitude":0.007845,"askPrice":48.99,"askSize":108,"bidPrice":48.96,"bidSize":800,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":48.44,"dividendRate":0.043053,"postHourTrading":{"tag":"盘后","latestPrice":48.44,"preClose":48.44,"latestTime":"19:30 EDT","volume":54475,"amount":2639178.46202,"timestamp":1789515007084,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.212501,"impliedVol":0.3388,"impliedVolPercentile":0.9124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.212501,"shares":305783111,"dividePrice":2.096102,"high":49.03,"amplitude":0.007845,"preClose":48.44,"low":48.65,"week52Low":45.77,"pbRate":"1.61","psRate":"2.34","week52High":55.49,"institutionHeld":0,"latestPrice":48.98,"committee":0.762115,"eps":2.229761,"divideRate":0.042795,"volume":42580,"delay":0,"ttmEps":2.229761,"open":48.7,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.38,"twentyDayClose":51.46,"sixtyDayClose":51.84,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-15","current":21.96648,"percent":0.458204,"low":16.637027,"twenty":17.78321,"median":20.257815,"eighty":21.038918,"high":22.07626,"avg":19.827678,"sd":1.473791,"marketCap":15047332456.73},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-15","current":20.136369,"twenty":17.78321,"median":20.257815,"eighty":21.038918,"marketCap":15047332456.73}],"updateTime":1789578821200},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658914350","title":"Analysts Are Bullish on These Utilities Stocks: Emera (EMA), Edenor SA (EDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658914350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658914350?lang=en_us&edition=fundamental","pubTime":"2026-08-12 00:00","pubTimestamp":1786464032,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Utilities sector as 2 analysts just weighed in on Emera (EMA) and Edenor SA (EDN) with bullish sentimen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-utilities-stocks-emera-ema-edenor-sa-edn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-utilities-stocks-emera-ema-edenor-sa-edn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4081","EDN","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990336","title":"Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990336?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Phase 2a clinical trial entitled \"A Phase IIa, single-arm, single-center,-- The VIRAGE2 study design incorporates feedback from both the. European Medicines Agency  and the U.S. Food and Drug. VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2. repeated dosing of VCN-01 may provide additional clinical benefit.-- The VIRAGE2 trial will evaluate the safety and feasibility of. administering at least 3 doses of VCN-01 given approximately 2. The trial is expected to enroll 6 evaluable patients. Results from. the VIRAGE2 study will inform the VCN-01 dosing regimen for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","L","BK4099","BK4081","TOVX","TM","03160","IDNA","EMA","BK4604","BK4107","GDOC","BK4585","BK4555","HYLG","BK4139","LU0210528500.USD","MEDX","LU2487616109.SGD","LU0053666078.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899239","title":"Press Release: Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899239?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, FranceNew cli","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4139","GCC","GT","BK4588","BK4539","EMA","BK4585","LENZ","BK4007","BK4119","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658229937","title":"Emera price target lowered to C$76 from C$77 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658229937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658229937?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:21","pubTimestamp":1786375270,"startTime":"0","endTime":"0","summary":"CIBC analyst Mark Jarvi lowered the firm’s price target on Emera (EMA) to C$76 from C$77 and keeps a Neutral rating on the shares. Published first ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-lowered-to-c76-from-c77-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-lowered-to-c76-from-c77-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658989585","title":"Barclays Keeps Their Hold Rating on Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989585","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658989585?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:57","pubTimestamp":1786348651,"startTime":"0","endTime":"0","summary":"Barclays analyst Michael Lonegan maintained a Hold rating on Emera today and set a price target of $53.00. According to TipRanks, Lonegan is a 3-st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658985367","title":"Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2658985367","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658985367?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:01","pubTimestamp":1786345260,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BARCELONA, Spain, August 10, 2026Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341553/0/en/oculis-signs-asset-purchase-agreement-with-accure-therapeutics-for-lead-candidate-privosegtor-fortifying-oculis-position-as-an-emerging-leading-neuro-ophthalmology-company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU0210528500.USD","LU0557290698.USD","LU1363072403.SGD","LU1854103824.USD","LU2111349929.HKD","LU2264538146.SGD","IAI","LU2089283258.USD","LU0006306889.USD","IE00BFMHRM44.USD","LU1162221912.USD","LU1548497426.USD","LU1989772840.SGD","ON","BK4124","LU1244550494.USD","BK4139","LU1861215975.USD","LU0053666078.USD","LU2487616109.SGD","LU1064131342.USD","KBWB","IE00BKVL7J92.USD","LENZ","BK4007","BK4127","IE00B3S45H60.SGD","LU0882574139.USD","LU2347655156.SGD","LU0348723411.USD","BK4516","EMA","LU1861219969.SGD","LU1244550577.SGD","LU0124384867.USD","LU2357305700.SGD","BK4081","LU0106831901.USD","LU0320765646.SGD","BK4141","DBB","LU2028103732.USD","ACT","LU1791710400.SGD","CDTI","LU1244550221.USD","OCS","LU1989772923.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100819060","title":"Stock Track | Emera Inc. Plunges 6.78% in Pre-market Trading After Q2 Earnings Miss Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1100819060","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100819060?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:36","pubTimestamp":1786106170,"startTime":"0","endTime":"0","summary":"Emera Inc. (NYSE: EMA) shares tumbled 6.78% in pre-market trading on Friday, as investors reacted to the company's second-quarter earnings report, which fell short of Wall Street expectations.The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657861214","title":"Emera Q2 Adjusted Earnings Fall, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2657861214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657861214?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:25","pubTimestamp":1786098349,"startTime":"0","endTime":"0","summary":"Emera  reported Q2 adjusted earnings Friday of 0.69 Canadian dollars  per share, down from CA$0.79 a year earlier.Analysts polled by FactSet expected CA$0.71.Revenue for the quarter ended June 30 was CA$2.01 billion, up from CA$1.99 billion a year earlier.Four analysts polled by FactSet expected CA$1.91 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CA","BK7129","BK4081","EMA.AU","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614259","title":"Emera Q2 Adj. EPS $0.50 Misses $0.56 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614259","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614259?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:02","pubTimestamp":1786096945,"startTime":"0","endTime":"0","summary":"Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.56 by 10.71 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61031475/emera-q2-adj-eps-0-50-misses-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMDE","BKMC","GXDW","FEBU","BK4081","EMA","VOTE","VGFPF","RGLO","JOYT","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614605","title":"Press Release: Emera Reports 2026 Second Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614605","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614605?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:00","pubTimestamp":1786096800,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia----August 07, 2026--Emera Inc.   reported 2026 second quarter financial results .Highlights--  Delivered Q2 2026 adjusted EPS2 of $0.69 and reported EPS of $0.34.--  Positioned to achieve 2026 adjusted EPS2 growth above the annual target. range of 5-7%3 and remain committed to 5-7% adjusted EPS2 growth through. --  Strengthened year-to-date operating cash flow4 by 8% versus the first. --  Safely advanced more than $1.7B of customer-focused infrastructure. investments in the first half of 2026, while remaining on track to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GXDW","VOTE","EMA","JOYT","DECU","RGLO","PMDE","BK4081","VGFPF","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614462","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614462?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:00","pubTimestamp":1786096800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ACM Research Inc. Class A                       2Q       .42       BMO. Algonquin Power & Utilities Corp.                2Q       .03   6:30 AM. Alpha Metallurgical Resources Inc.               2Q      (.43)  7:30 AM. Construction Partners Inc. Class A              3Q      1.01       BMO. Kimbell Royalty Partners LP                      2Q       .23   7:00 AM. Park Hotels & Resorts Inc.                        2Q       .25       AMC. Plains All American Pipeline L.P.                2Q       .38   7:30 AM. Plains GP Hldgs LP Class A                      2Q       .46   7:30 AM. Rapid Micro BioSyss Inc. Class A                2Q      (.24)      BMO. Spectrum Brands Hldgs Inc.                       3Q      1.46   6:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CODI","DMAC","ATMU","ALC","ACVA","ARQ","ACHR","AIOT","AAON","ALMR","ANAB","AQN","B","CGC","AXSM","DCBO","ELVA","CBLL","DH","UA","ELTX","ANIP","BCSF","ACMR","ACH","CIB","BKD","EMBC","CNTY","DCGO","CRC","APEI","EMA","AMTM","AMR","CECO","ASTS","BODI","DCH","BTDR","CCAP","CTEV","BZH","BWMN","CEVA","ACM","CAMT","CNDT","BBIO","CLMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657310416","title":"Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2657310416","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657310416?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340188/0/en/Annexon-Reports-First-U-S-and-European-Patient-Cohort-of-GBS-FORWARD-Study-Demonstrated-Rapid-Positive-Clinical-Responses-in-All-Tanruprubart-Treated-Patients-Within-One-Week.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","EMA","BK4585","EPV","BK4215","SPRE","BK4081","ICU","ANNX","BK4139","MAA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633011","title":"Press Release: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633011?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:32","pubTimestamp":1786015920,"startTime":"0","endTime":"0","summary":"--  PepGen has fully enrolled the 10 mg/kg MAD cohort of FREEDOM2,with 7 of 8 participants having completed dosing. Data from this. cohort is on track to be reported in November.--  Based on the review of available safety data from the 10 mg/kg. MAD cohort and the open-label extension  study, an. advancing the FREEDOM2 trial into the third and highest dose. cohort . The DSMB also approved dose escalation in the. OLE study from 5 mg/kg to 10 mg/kg. Read the full release here.--  Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in. the first half of 2027. Pending results from Cohorts 2 and 3,PepGen plans to engage with regulators in an end of Phase 2 . meeting to discuss plans for the registrational program.OLE, 6 of 8 participants from the 5 mg/kg FREEDOM2 cohort have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657817635","title":"Press Release: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2657817635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657817635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015800,"startTime":"0","endTime":"0","summary":"-- Announced advancement of izicopan in ANCA-associated vasculitis  and. select renal diseases; clinical preparations ongoing as planned. -- Initiated feasibility assessment for broadened strategy for AAV in Europe. Reported new pre-clinical data supporting the safety and differentiation. of izicopan as a next-generation oral inhibitor of C5aR. -- Pharmacokinetic  bridging study in China expected to start late this. year, with a goal to accelerate izicopan proof-of-concept studies in. -- Virtual Capital Markets Day planned for October 8, 2026 in the morning ET. -- Cash, cash equivalents and marketable securities totaled EUR158.4 million. on June 30, 2026, including net proceeds from the underwritten public. offering completed in May, expected to fund ongoing operations and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KBWY","PK","BK4087","IFRX","BK4139","BK4181","BK4218","CHMP","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687386","title":"Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687386?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:30","pubTimestamp":1786012200,"startTime":"0","endTime":"0","summary":"--  The Company advanced multiple global oncology and immunology programs. toward key clinical and regulatory milestones, with significant pipeline. --  Global Phase 1 data for zocilurtatug pelitecan  in combination. with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026;planned initiation of a registrational Phase 3 study later this year. --  Registrational Phase 3 DLLEVATE study evaluating zoci in second-line. plus SCLC remains on track, with enrollment expected to be completed in. the first half of 2027, supporting a potential U.S. accelerated approval. --  Global Phase 1/1b study of ZL-1503, a potential first-in-class. long-acting IL-13/IL-31R<ALPHA> bispecific antibody for the treatment of. atopic dermatitis, continues to advance, with initial first-in-human data. --  KarXT successfully launched in mainland China; encouraging early launch. trends building momentum ahead of potential NRDL inclusion. --  Total revenues of $106.3 million in the second quarter of 2026;","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4231","ADC","BK4585","EMA","BK4232","R","BK4183","IND","BK4139","IE0009354923.USD","BK4588","NETL","ZLAB","BK4081","BK4080","BK4531","BK4548","ODD","LU2488822045.USD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657989540","title":"Emera Inc Expected to Post Earnings of 49 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657989540","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657989540?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:37","pubTimestamp":1785937026,"startTime":"0","endTime":"0","summary":"Emera Inc <EMA.TO> expected to post earnings of49cents a share - Earnings PreviewEmera IncEMA.TOis expected to  report resultson August 7 for the period ending June 30 2026LSEG's mean analyst estimate for Emera Inc is for earnings of 49 cents per share.The one available analyst rating on the shares is \"hold\".The average consensus recommendation for the electric utilities peer group is also \"Hold\".Wall Street's median 12-month price target for Emera Inc is $55.00, about 5% above its last closing price of $52.37This summary was machine generated August 5 at 13:37 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44225N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376400","title":"Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376400","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376400?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754800,"startTime":"0","endTime":"0","summary":"Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug.  03, 2026  (GLOBE NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337371/0/en/Can-Fite-Launches-First-Clinical-Program-for-Piclidenoson-in-the-Rare-Genetic-Disease-Lowe-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4006","HCC","COAL","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321081","title":"Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321081","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656321081?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:00","pubTimestamp":1785744000,"startTime":"0","endTime":"0","summary":"The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical needThe FDA c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337249/0/en/Oculis-Announces-Positive-FDA-Pre-IND-Feedback-Supporting-Privosegtor-Development-Strategy-for-Treatment-of-Acute-Multiple-Sclerosis-Relapses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","LU2298322129.HKD","LU2089284900.SGD","LU0557290698.USD","LU2111349929.HKD","BK4605","LU0724618433.USD","BK4127","LABU","LU0106831901.USD","LU0006306889.USD","IND","BK4581","LU0098860793.USD","MORT","LU2487616109.SGD","IE00BFMHRM44.USD","LU2347655156.SGD","IE00BZ1G4Q59.USD","KBWB","OCS","LU1791710582.SGD","LU1988902786.USD","LU1854103824.USD","BK4081","EMA","LU2360107325.USD","BK4110","LU2133065610.SGD","IAI","LU1791710400.SGD","LU0053666078.USD","RGC","LU1244550577.SGD","LU1861220033.SGD","BK4534","LU0106261372.USD","LU1989772840.SGD","REM","ARR","LU2023251221.USD","ON","LU1978683503.SGD","LU0158827781.USD","BK4512","BK4516","IE00B3S45H60.SGD","LU0795875169.SGD","LU1363072403.SGD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656347940","title":"Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2656347940","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656347940?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:28","pubTimestamp":1785727695,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma and Menarini Group previously announced that the EMA’s CHMP issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) in European patients with primary hypercholesterolemia and mixed dyslipidemia.\nThis opinion, backed by extensive Phase 2 and Phase 3 data showing meaningful LDL-C reductions with placebo-like tolerability, could reshape NewAmsterdam’s commercial outlook through...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/why-newamsterdam-pharma-nams-is-down-62-after-ema-backs-ubes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/why-newamsterdam-pharma-nams-is-down-62-after-ema-backs-ubes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EMA","BK4081","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136721569","title":"Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1136721569","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136721569?lang=en_us&edition=fundamental","pubTime":"2026-07-31 11:26","pubTimestamp":1785468396,"startTime":"0","endTime":"0","summary":"Abstract Emera Inc. will report second-quarter 2026 results on August 7, 2026 Pre-Market; current expectations center on revenue of 2.03 billion Canadian dollars, EBIT of 473.42 million Canadian...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Emera Inc. revenue is expected to increase by 15.89% this quarter, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}